TheraRadar

Pharma Intelligence, Simplified

Landscape → Oncology

Hodgkin Lymphoma

491 clinical trials

256 active
/
491 total (since 2015)
131
Phase 1 Active
269 total
158
Phase 2 Active
284 total
18
Phase 3 Active
31 total
5
Phase 4 Active
5 total

Top Sponsors (Industry)

Sorted by active Active Done Failed
Merck 3 6 0
AbbVie 3 1 1
Sichuan Baili Pharmaceutical Co., Ltd. 3 0 0
Takeda 2 1 0
AstraZeneca 2 1 0
ImmunityBio, Inc. 2 0 1
Akeso 2 1 0
Sana Biotechnology 2 0 0
Chongqing Precision Biotech Co., Ltd 2 0 0
Guangdong Ruishun Biotech Co., Ltd 2 0 0
Aurigene Discovery Technologies Limited 2 0 0
Tessa Therapeutics 2 0 0
Roche 1 2 1
Seagen, a wholly owned subsidiary of Pfizer 1 0 1
Sanofi 1 0 1
NCT05675410 RECRUITING
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
National Cancer Institute (NCI) n=1,875
NCT03844048 ACTIVE NOT RECRUITING
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie n=165
NCT05991388 RECRUITING
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
University of Birmingham n=210
NCT04685616 RECRUITING
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
University College, London n=1,042
NCT07256158 NOT YET RECRUITING
PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma
Fondazione Italiana Linfomi - ETS n=518
NCT06520163 RECRUITING
Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
The Affiliated People's Hospital of Ningbo University n=99
NCT03907488 ACTIVE NOT RECRUITING
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
National Cancer Institute (NCI) n=994
NCT02166463 ACTIVE NOT RECRUITING
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma
National Cancer Institute (NCI) n=600
NCT04459416 ACTIVE NOT RECRUITING
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma
Memorial Sloan Kettering Cancer Center n=299
NCT07202052 RECRUITING
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)
Monash University n=900
NCT05595447 RECRUITING
Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
Hospital Regional de Alta Especialidad del Bajio n=20
NCT06170489 RECRUITING
A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
Shanghai Junshi Bioscience Co., Ltd. n=185
NCT06563245 RECRUITING
Brentuximab Vedotin for Newly Diagnosed CHL in Chinese CAYA Based on PET/CT Assessment
Children's Cancer Group, China n=96
NCT04638790 RECRUITING
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia n=300
NCT06465446 NOT YET RECRUITING
A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. n=202
NCT02661503 ACTIVE NOT RECRUITING
HD21 for Advanced Stages
University of Cologne n=1,500
NCT02684708 ACTIVE NOT RECRUITING
Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents
University of Giessen n=2,200
NCT05244642 RECRUITING
A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma
Akeso n=60
NCT07450508 COMPLETED
Study of Bendamustine, Gemcitabine and Vinorelbine Regimen in Relapsed/Refractory Classical Hodgkin Lymphoma
Cairo University n=88
NCT04486391 TERMINATED
Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma
BeiGene n=3
NCT02684292 COMPLETED
Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)
Merck Sharp & Dohme LLC n=304
NCT03159897 COMPLETED
FIL Study on ABVD DD-DI as Upfront Therapy in HL.
Fondazione Italiana Linfomi - ETS n=500
NCT05181540 TERMINATED
A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation
Angiocrine Bioscience n=130
NCT04745832 TERMINATED
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
MEI Pharma, Inc. n=82
NCT03595800 COMPLETED
Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen
Institut Paoli-Calmettes n=9
NCT05711628 WITHDRAWN
A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma
National Cancer Institute (NCI)
NCT03265574 COMPLETED
PROACT: Can we Prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma?
South Tees Hospitals NHS Foundation Trust n=111
NCT02787239 COMPLETED
Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL
Shanghai Henlius Biotech n=407
NCT02576275 WITHDRAWN
A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
SecuraBio
NCT02910063 COMPLETED
Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL
Amgen n=41
NCT03242902 COMPLETED
To Decrease Fatigue With Light Therapy
The Netherlands Cancer Institute n=166

Data: ClinicalTrials.gov